Skip to main content
. 2023 May 15;12(13):14317–14326. doi: 10.1002/cam4.6108

FIGURE 6.

FIGURE 6

A patient case showed ctDNA dynamics and CT images at different time points during treatment. The 72‐year‐old man received six cycles of first‐line pembrolizumab monotherapy. The ctDNA burden showed an 88.63% decrease from baseline to Day 30 while the patient achieved PR on Day 59.